Work Here?
Farallon Capital Management
Work Here?
Global investment firm managing assets
Farallon Capital Management
Work Here?
Global investment firm managing assets
Overview
Farallon Capital Management is a global investment firm that manages public and private assets for a diverse set of clients, including institutions, high-net-worth individuals, and family offices. It uses bottom-up fundamental analysis to pick investments and then applies ideas across global markets, aiming for solid, risk-conscious returns. The firm earns management fees and performance incentives, tying its compensation to client results, and emphasizes collaboration and aligned incentives. Its goal is to deliver superior risk-adjusted returns for clients over time through disciplined research and adaptable strategies.
About Farallon Capital Management
Industries
Quantitative Finance
Financial Services
Company Size
201-500
Company Stage
N/A
Total Funding
$10.3B
Headquarters
San Francisco, California
Founded
1986
Simplify's Take
What believers are saying
- InflaRx $150M investment on May 7, 2026, taps anti-inflammatory biotech growth.
- €761M Isemia co-investment expands European healthcare real estate with aging demographics.
- New CyberArk and Synopsys positions capture cybersecurity and AI chip design surges.
What critics are saying
- AUM drops from $39B to $21.2B erodes management fee revenue immediately.
- SPY, MSFT, AMZN concentration crushes returns in 2026 market correction.
- Bitwise 10 Crypto ETF triggers massive losses in 2027 crypto crash.
What makes Farallon Capital Management unique
- Farallon pioneered absolute return investing since Tom Steyer founded it in 1986.
- Firm pursues multi-strategy across risk arbitrage, credit, and real estate globally.
- Manages $21.2 billion for endowments and high-net-worth individuals using bottom-up analysis.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$10.3B
Above
Industry Average
Funded Over
0 Rounds
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Company News
Jena, Germany, May 6, 2026 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. All ordinary shares in the offering are being sold by the Company. The offering is expected to close on May 7, 2026, subject to the satisfaction of customary closing conditions
A graduate of the class of 1989, Daniel Rigny heads TwentyTwo Real Estate, an independent group dedicated to real estate investment in Europe, which he founded in 2012.
Mirador Therapeutics, a San Diego, CA-based clinical-stage precision medicine company developing new therapies for immune-mediated inflammatory and fibrotic diseases, raised $250M in Series B funding
Mirador Therapeutics raises $250M Series B, eyes IPO. CEO Mark McKenna reveals clinical programs for Crohn's, IPF, RA and colitis, with 10+ data readouts expected by 2027.
Financing co-led by RA Capital Management, Fidelity Management & Research Company, and Janus Henderson Investors
There are no jobs for Farallon Capital Management right now.
Find jobs on Simplify and start your career today
About Farallon Capital Management
Industries
Quantitative Finance
Financial Services
Company Size
201-500
Company Stage
N/A
Total Funding
$10.3B
Headquarters
San Francisco, California
Founded
1986
There are no jobs for Farallon Capital Management right now.
Find jobs on Simplify and start your career today